triple glp-1/gip/glucagon receptor agonist parkinson's disease glp-1 gip glucagon clinical trial Current Insights, Advantages and Challenges of Retatrutide Explained: How the Triple

Diabetes 58 , 299301 (2009)

doi: 10.1185/030079905x75078

GLP-1 is a product of pre-pro-glucagon gene expression in the L-cells of the intestinal mucosa

One of last years largest start-up launches belonged to Kailera Therapeutics, a US firm backed by $400 million in venture funds thats based on four drug candidates licensed from Hengrui for weight loss and metabolic conditions

The phase 3 study showed: - Significant improvement in muscle and skin symptoms over placebo - Greater steroid tapering success among patients - A safety profile consistent with prior studies, with no cardiovascular clotting events observed Impact: If approved, this once-daily pill could offer patients a much-needed alternative to high-dose steroids and IV therapies